Singapore, June 9 -- The PublicHealth Systems Research Institute (PHRI) and Novo Nordisk Pharma (Thailand) Co. havesigned a major Memorandum of Understanding (MoU) between the public and private sectors to raise the standard of clinical research and support the expansion of clinical research opportunities in Thailand.

Thailand is classified as an opportunity tier due to the large number of patients who are ready to be treated. Therefore, there is a great opportunity for sponsors to find volunteers to participate in research and development projects for new drugs or products. It can replace traditional countries such as Europe or the United States, which have high research costs.

Dr Supakit Sirilak, Director of the Public Health Systems ...